Madrigal Pharmaceuticals Secures U.S. Patent for Rezdiffra Through 2044

Madrigal Pharmaceuticals has secured a U.S. patent for its FDA-approved treatment Rezdiffra, which is used for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. The patent, covering Rezdiffra's commercial weight-threshold dosing regimen, will provide market protection through September 30, 2044, and will be listed in the FDA's Orange Book, ensuring its exclusivity. Following the announcement, Madrigal's shares rose notably, reflecting investor optimism supported by an average analyst price target of $422 and a consensus brokerage rating of 'Outperform.' The company reported strong financials for Q1 2025, including net sales of $137.3 million, a significant increase in patients using Rezdiffra, and a robust cash position nearing $850 million. CEO Bill Sibold highlighted the patent as a pivotal milestone that will enable continued innovation for MASH patients. Overall, the patent solidifies Madrigal's market position and enhances the outlook for its lead therapeutic product.